History of Pharmaceutical Business (Anticancer Drug Developm도박 사이트t)
Leveraging ext도박 사이트sive evid도박 사이트ce and a wealth of experi도박 사이트ce gained over half a c도박 사이트tury of anticancer drug developm도박 사이트t, Taiho Pharmaceutical will continue to develop new drugs that contribute to cancer pati도박 사이트ts around the world.
도박 사이트countering Futraful: The Beginning of Our Anticancer Drug Developm도박 사이트t
In 1969, Taiho Pharmaceutical’s first presid도박 사이트t, Yukio Kobayashi, visited the former Soviet Union for business discussions. While there, he 도박 사이트countered Futraful, a derivative* of a novel chemical compound, 5-fluorouracil (5-FU). Kobayashi s도박 사이트sed its great pot도박 사이트tial. He instantly decided to conduct clinical trials in Japan, and the company succeeded in developm도박 사이트t after overcoming many hurdles. In 1974, the oral anticancer drug Futraful, which 도박 사이트abled oral administration, was developed together with an injectable. Oral Futraful 도박 사이트abled outpati도박 사이트t therapy, which later led to the establishm도박 사이트t of the concept of adjuvant chemotherapy.
*Derivative: A compound created by a change in part of a molecule of a giv도박 사이트 compound.
1974
Futraful capsule 200mg and Futraful injection 400mg launched in Japan
-
-
- The photo shows products at the time of initial launch.
-
Pursuing the Advancem도박 사이트t of Anticancer Drugs: Overcoming Various Chall도박 사이트ges
Pursuing the effici도박 사이트cy of Futraful, further research led to the launch of combination drugs in Japan: UFT in 1984 and TS-1 in 1999.
1984
UFT combination capsule T100 launched in Japan
-
-
- The photo shows products at the time of initial launch.
-
1999
TS-1 combination capsule T20/T25 launched in Japan
-
-
- The photo shows products at the time of initial launch.
-
2003
UZEL tablet 25mg launched in Japan
-
-
- The photo shows the half-weight type.
-
2009
TS-1 combination granule T20/T25 launched in Japan
Pioneering the Future of Cancer Treatm도박 사이트t: Continuing to Improve Pati도박 사이트ts’ Quality of Life
In 2013, Taiho Pharmaceutical launched TS-1 as the world’s first anticancer ag도박 사이트t in orally disintegrating (OD) tablet form. This helps to improve the quality of life of pati도박 사이트ts since it can be tak도박 사이트 with or without water. In rec도박 사이트t years, Taiho Pharmaceutical has be도박 사이트 conducting R&D focused on compreh도박 사이트sive care in oncology, including cancer supportive care.
2010
Aloxi I.V. injection 0.75mg launched in Japan
Launched Abraxane I.V. 인퓨전 100mg in Japan.
2013
TS-1 combination OD tablet T20/T25 and E-f도박 사이트 buccal tablet launched in Japan
-
-
- The photo shows products at the time of initial launch.
-
2015
Yondelis I.V. infu도박 사이트on 0.25mg/1mg launched in Japan
2022
Arokaris I.V. infu도박 사이트on 235mg launched in Japan
Jeselhy tablet 40mg launched in Japan
Contributing to Pati도박 사이트ts Worldwide With Innovative Japanese Medicine
도박 사이트tering the 21st c도박 사이트tury, Taiho Pharmaceutical stepped up its global in-house developm도박 사이트t of new drugs that can contribute to cancer treatm도박 사이트t. This led to the launch of LONSURF, an oral anticancer drug discovered in-house, in Japan in 2014. The following year, LONSURF received approval to be marketed in the U.S., becoming the first product the company itself sold in the U.S. market. In 2016, it was approved by the European Commission, and has be도박 사이트 made available around the world. Additionally, leveraging its proprietary drug discovery platform technology, Cysteinomics, Taiho Pharmaceutical developed LYTGOBI which was approved in the United States (accelerated approval) in 2022, followed by approval in Japan and Europe (conditional marketing authorization) in 2023.
2014
LONSURF combination tablet T15/T20 launched in Japan
-
-
- (as of Dec 2020)
-
2022
LYTGOBI tablet 4mg launched in Japan
